Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 2 · 2000–2026
Showing the 50 most relevant studies, sorted by most relevant.
Indian Journal of Traditional Knowledge, 2025
F Dantas, H Rampes
British Homeopathic Journal, 2000
L Long, E Ernst
British Homeopathic Journal, 2001
Pankhuri Misra, Chintamani Nayak, Abhijit Chattopadhyay, et al.
Homeopathy, 2020
- India
- Materia Medica
- Placebos
M. Van Wassenhoven, M. Goyens, Pierre Dorfman, et al.
Homeopathy, 2024
: Sruthi Krishna
Journal of Medical Case Studies, 2023
Bernhard Wegener
2024
Are courts, as institutions aimed at individual justice, suitable institutions for dealing with the climate crisis? Could they guide the social and global transformation processes that are certainly necessary? Bernhard Wegener takes a clear stand against the “sweet illusion of climate justice“.
Abstract licence: CC BY-SA 4.0
M. Wassenhoven, M. Goyens, Pierre Dorfman, et al.
International Journal of High Dilution Research - ISSN 1982-6206, 2025
Background and Objectives Over the past decade, research using various methods has claimed the material nature of high homeopathic potencies. The current study aims to verify these findings using pH measurements. Methods Six independent serial dilutions of commonly used homeopathic medicines, either soluble (Arnica, Belladona, Gelsemium, Pyrogenium, Pyrogenium crudum, Kalium muriaticum) or insoluble (Cuprum, Argentum, Silicea), and prepared according to European Pharmacopoeia standards were pooled and used for pH measurement. We compared the homeopathic dynamisations (DYNs) in pure water with their potentized controls and with simple dilutions (DILs) up to 30cH/10−60. We also tested the influence of the container (Glass or Polyethylene terephthalate ‘PET’) on the solvent controls. Results The different manufacturing processes of the stocks (trituration required or not) influence the pH results. Stock heating process changes the pH of the entire production line. pH measurements can distinguish a dynamised production line from its dynamised solvent but not always from their simple dilution. The presence of a stock at the beginning of a homeopathic manufacturing process modifies the electrical behaviour of the solvent during all successive dilutions, even at the highest dilutions/dynamisations. The container has a significant effect on the electric field indicating the involvement of the atmosphere and leaching processes. Conclusion In homeopathic potentisations of all stocks, an electric field can be measured with specific intensities, even when diluted beyond Avogadro’s number. Homeopathic potentisation is not a simple solvent dilution. The starting material, the solvent used, the type of container and the manufacturing method influence the characteristics of these electric fields. The process of heating the stock should be avoided. The reasons for the presence of these pH values and their stability are not known, but they are most likely related to the presence of nanometric superstructures in these preparations. The role of pH in the manufacturing process and in the effects of homeopathic medicines should be further investigated.
Abstract licence: CC BY-NC-SA
Quamar Sultana, R. Pal, S. Saha, et al.
Homeopathy, 2025
Yevgenia Svitlychna, V.V. Savina, Наталія Томарєва
Zenodo (CERN European Organization for Nuclear Research), 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.